Clinical Read2026-06-02

Izalontamab brengitecan vs chemotherapy - (PANKU-Esophagus01)

Name: Izalontamab brengitecan vs chemotherapy - (PANKU-Esophagus01)
Start: 2026-06-02

Bristol-Myers Squibb CompanyBMY

Indication: Recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
Stage: phase3
Event: Phase 3